Adenoviral Producer Cells

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2011 Oct 14

PMID 21994701

Citations 46

Authors

Imre Kovesdi

Susan J Hedley

Affiliations

Soon will be listed here.

Abstract

Adenovirus (Ad) vectors, in particular those of the serotype 5, are highly attractive for a wide range of gene therapy, vaccine and virotherapy applications (as discussed in further detail in this issue). Wild type Ad5 virus can replicate in numerous tissue types but to use Ad vectors for therapeutic purposes the viral genome requires modification. In particular, if the viral genome is modified in such a way that the viral life cycle is interfered with, a specific producer cell line is required to provide trans-complementation to overcome the modification and allow viral production. This can occur in two ways; use of a producer cell line that contains specific adenoviral sequences incorporated into the cell genome to trans-complement, or use of a producer cell line that naturally complements for the modified Ad vector genome. This review concentrates on producer cell lines that complement non-replicating adenoviral vectors, starting with the historical HEK293 cell line developed in 1977 for first generation Ad vectors. In addition the problem of replication-competent adenovirus (RCA) contamination in viral preparations from HEK293 cells is addressed leading to the development of alternate cell lines. Furthermore novel cell lines for more complex Ad vectors and alternate serotype Ad vectors are discussed.

Citing Articles

Effective protection of biological tissues from severe blunt force injury by engineered nanoscale liquid flow.

Yang F, Zhu R, Zheng A, An R, Lu W, Liang Y Sci Rep. 2024; 14(1):28947.

PMID: 39578545 PMC: 11584685. DOI: 10.1038/s41598-024-80490-3.

Establishment of a novel cell line for producing replication-competent adenovirus-free adenoviruses.

Han E, Kim Y BMC Biotechnol. 2024; 24(1):67.

PMID: 39334326 PMC: 11429178. DOI: 10.1186/s12896-024-00894-x.

Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.

Park A, Lee J J Microbiol. 2024; 62(7):491-509.

PMID: 39037484 DOI: 10.1007/s12275-024-00159-4.

Expanding the Scope of Adenoviral Vectors by Utilizing Novel Tools for Recombination and Vector Rescue.

Fischer J, Fedotova A, Buhler C, Darriba L, Schreiner S, Ruzsics Z Viruses. 2024; 16(5).

PMID: 38793540 PMC: 11125593. DOI: 10.3390/v16050658.

Animal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post Covid-19 Perspective.

Demirden S, Kimiz-Gebologlu I, Oncel S ACS Omega. 2024; 9(15):16904-16926.

PMID: 38645343 PMC: 11025085. DOI: 10.1021/acsomega.3c10484.

References

Weinberg D, Ketner G . A cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus type 2. Proc Natl Acad Sci U S A. 1983; 80(17):5383-6. PMC: 384260. DOI: 10.1073/pnas.80.17.5383. View

He T, Zhou S, DA COSTA L, Yu J, Kinzler K, Vogelstein B . A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998; 95(5):2509-14. PMC: 19394. DOI: 10.1073/pnas.95.5.2509. View

Graham F . Growth of 293 cells in suspension culture. J Gen Virol. 1987; 68 ( Pt 3):937-40. DOI: 10.1099/0022-1317-68-3-937. View

Kremer E, Boutin S, Chillon M, Danos O . Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J Virol. 1999; 74(1):505-12. PMC: 111562. DOI: 10.1128/jvi.74.1.505-512.2000. View

Gao W, Robbins P, Gambotto A . Human adenovirus type 35: nucleotide sequence and vector development. Gene Ther. 2003; 10(23):1941-9. DOI: 10.1038/sj.gt.3302097. View

Nevins J . Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell. 1981; 26(2 Pt 2):213-20. DOI: 10.1016/0092-8674(81)90304-4. View

Parks R . Adenovirus protein IX: a new look at an old protein. Mol Ther. 2004; 11(1):19-25. DOI: 10.1016/j.ymthe.2004.09.018. View

Gao G, Engdahl R, Wilson J . A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus. Hum Gene Ther. 2000; 11(1):213-9. DOI: 10.1089/10430340050016283. View

Brough D, Lizonova A, Hsu C, Kulesa V, Kovesdi I . A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol. 1996; 70(9):6497-501. PMC: 190687. DOI: 10.1128/JVI.70.9.6497-6501.1996. View

10.

Hehir K, Armentano D, Cardoza L, Choquette T, Berthelette P, White G . Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J Virol. 1996; 70(12):8459-67. PMC: 190936. DOI: 10.1128/JVI.70.12.8459-8467.1996. View

11.

Murakami P, Havenga M, Fawaz F, Vogels R, Marzio G, Pungor E . Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches. J Virol. 2004; 78(12):6200-8. PMC: 416523. DOI: 10.1128/JVI.78.12.6200-6208.2004. View

12.

Abbink P, Lemckert A, Ewald B, Lynch D, Denholtz M, Smits S . Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007; 81(9):4654-63. PMC: 1900173. DOI: 10.1128/JVI.02696-06. View

13.

Reddy P, Idamakanti N, Chen Y, Whale T, Babiuk L, Mehtali M . Replication-defective bovine adenovirus type 3 as an expression vector. J Virol. 1999; 73(11):9137-44. PMC: 112946. DOI: 10.1128/JVI.73.11.9137-9144.1999. View

14.

Vlachaki M, Hernandez-Garcia A, Ittmann M, Chhikara M, Aguilar L, Zhu X . Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther. 2002; 6(3):342-8. DOI: 10.1006/mthe.2002.0669. View

15.

Bridge E, Ketner G . Redundant control of adenovirus late gene expression by early region 4. J Virol. 1989; 63(2):631-8. PMC: 247733. DOI: 10.1128/JVI.63.2.631-638.1989. View

16.

Segerman A, Atkinson J, Marttila M, Dennerquist V, Wadell G, Arnberg N . Adenovirus type 11 uses CD46 as a cellular receptor. J Virol. 2003; 77(17):9183-91. PMC: 187375. DOI: 10.1128/jvi.77.17.9183-9191.2003. View

17.

Fallaux F, Bout A, van der Velde I, van den Wollenberg D, Hehir K, Keegan J . New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther. 1998; 9(13):1909-17. DOI: 10.1089/hum.1998.9.13-1909. View

18.

Lusky M . Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther. 2005; 16(3):281-91. DOI: 10.1089/hum.2005.16.281. View

19.

Reddy P, Ganesh S, Limbach M, Brann T, Pinkstaff A, Kaloss M . Development of adenovirus serotype 35 as a gene transfer vector. Virology. 2003; 311(2):384-93. DOI: 10.1016/s0042-6822(03)00161-2. View

20.

Yang Y, Nunes F, Berencsi K, Furth E, Gonczol E, Wilson J . Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994; 91(10):4407-11. PMC: 43794. DOI: 10.1073/pnas.91.10.4407. View